GIC-102

N/A

Report date: 2024/07/10 20:00:41

Base Information

Drug NameGIC-102
Drug Alias NameTOP NK cell therapy(Gi Cell)GIC-102
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsMultiple Myeloma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGi Cell Inc
China Registration ClassN/A

Develop Information

Active CompaniesGi Cell Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsMultiple Myeloma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A